ABMD

Abiomed, Inc. (ABMD) | Rumor.io

Abiomed

ABMD

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ABMD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Dec 27

ABMD has a top analyst price target for next week, although the exact number is not specified.
The stock's peak profit for the last 6 expired option alerts for ABMD is 104.08%, and it has a high OI range of 380.00 to 380.00 for option expiration 01/20/2023.
ABMD has a sell rating based on 27 signals on the 30-min chart, and it is in a +0.3% uptrend, advancing for three consecutive days on December 19, 2022.

Generated by AI

Sentiment

Of the messages about ABMD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +91.11
Bearish	—	—	—	0% -91.11

Bullish· Nov 1

Abiomed, Inc. ($ABMD) has been acquired by Johnson & Johnson ($JNJ) for $380 per share, a deal worth $16.6 billion.
The acquisition highlights the growth potential of the medtech sector, with Abiomed's stable and improving EPS expectations and solid growth prospects over the next 3-5 years.
Some investors have seen significant returns on their investments, with some call options increasing in value by over 2,000% in just 10 days.

Bearish· Nov 1

$JNJ's acquisition of ABMD for $380/share may undervalue the company, as its 2018 ATHs were higher.
Several analysts have downgraded ABMD, with William Blair and Piper Sandler moving their ratings to Market Perform and Neutral, respectively.
ABMD's IV premium was destroyed despite a 50% pop, suggesting that the price may have been driven by speculation rather than fundamentals.

Generated by AI

Topics

Of the messages about ABMD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Earnings· Jan 28

Abiomed, Inc. ($ABMD) reported Q3 2021 earnings of $1.17, beating the consensus estimate of $1.15.
The company's Q3 revenue reached a record $232 million, a 5% year-over-year increase, with a 31% operating margin.
Abiomed guided Q4 2021 revenue to $225-235 million, with a beat on Q3 earnings and revenue expectations.

Analysts· Nov 2

BTIG Research upgraded Abiomed ($ABMD) from neutral to buy with a $450 price target.
LEERINK reiterated an Outperform rating on Abiomed ($ABMD) with a price target of $450.
BTIG Research upgraded Abiomed ($ABMD) from neutral to buy with a $450 price target.

Announcements· Dec 22

Johnson & Johnson has completed its acquisition of Abiomed for $380 per share in cash, plus one non-tradeable contingent value right (CVR) of up to $35.
The acquisition was completed with 57% of Abiomed shares tendered, and Abiomed will operate as a standalone business within Johnson & Johnson's MedTech segment.
Abiomed has received FDA approval for its Impella ECP Pivotal heart pump, and the first patients have been enrolled in the pivotal clinical trial.

Technical Analysis· Oct 29

$ABMD has formed a bottom with a 28% decline, with some traders seeing this as a buying opportunity.
The stock is showing a golden cross on the 15-minute chart, indicating a potential upward trend.
A Fibonacci retracement level of 0.38 has been identified as a possible upside target for the stock.

Generated by AI

Community

Of the messages about ABMD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	2.5%
Newcomers	—	—	100%	97.5%

Regulars· Dec 22

Abiomed's quarterly revenue growth rate YoY is 7.20%, ranking 2445 out of 5752 companies in the database.
Johnson & Johnson has completed its acquisition of Abiomed, with the company filing necessary forms with the SEC, including a Form 14D9/A and Form SC TO-T/A.
Abiomed's Impella ECP Pivotal has been approved by the FDA, with the first patients enrolled in the pivotal clinical trial.

Newcomers· Dec 22

The acquisition of Abiomed by Johnson & Johnson has been completed, with Abiomed shareholders receiving $380 in cash plus a non-tradeable CVR worth up to $35.
Newcomers are adding to their positions in Abiomed, citing the potential for a top 3 position in their portfolio and a good risk-to-reward ratio.
Abiomed is expected to operate as a standalone business within Johnson & Johnson's MedTech segment, with a positive trend in trading volumes and a potential price target for next week.

Generated by AI

News

J&J's MedTech Performance Slows in Q2: Will Sales Improve in H2?

Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Johnson & ⁠Johnson also increased its full-year sales and ⁠profit ‌forecast.

2mo agoCNBC

J&J medtech miss overshadows earnings beat

2mo agoReuters

Also Discussed

Investors talking about ABMD also mention

#	Name	Attention
1	Edwards Lifesciences CorporationEW	0%new
2	CSII - Cardiovascular Systems, Inc.	——
3	SWAV - ShockWave Medical, Inc.	——
4	HealthEquity, Inc.HQY	0%new
5	Stryker CorporationSYK	0.01%+0.01
6	iRadimed CorporationIRMD	0%0
7	Align Technology Inc.ALGN	0%new
8	Tandem Diabetes Care, Inc.TNDM	0%new
9	Ani Pharmaceuticals, Inc.ANIP	0%new
10	Deluxe CorpDLX	0%new

Abiomed, Inc.

Location

Social

What share of all stock conversation is about ABMD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Dec 27

ABMD has a top analyst price target for next week, although the exact number is not specified.
The stock's peak profit for the last 6 expired option alerts for ABMD is 104.08%, and it has a high OI range of 380.00 to 380.00 for option expiration 01/20/2023.
ABMD has a sell rating based on 27 signals on the 30-min chart, and it is in a +0.3% uptrend, advancing for three consecutive days on December 19, 2022.

Generated by AI

Sentiment

Of the messages about ABMD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +91.11
Bearish	—	—	—	0% -91.11

Bullish· Nov 1

Abiomed, Inc. ($ABMD) has been acquired by Johnson & Johnson ($JNJ) for $380 per share, a deal worth $16.6 billion.
The acquisition highlights the growth potential of the medtech sector, with Abiomed's stable and improving EPS expectations and solid growth prospects over the next 3-5 years.
Some investors have seen significant returns on their investments, with some call options increasing in value by over 2,000% in just 10 days.

Bearish· Nov 1

$JNJ's acquisition of ABMD for $380/share may undervalue the company, as its 2018 ATHs were higher.
Several analysts have downgraded ABMD, with William Blair and Piper Sandler moving their ratings to Market Perform and Neutral, respectively.
ABMD's IV premium was destroyed despite a 50% pop, suggesting that the price may have been driven by speculation rather than fundamentals.

Generated by AI

Topics

Of the messages about ABMD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Earnings· Jan 28

Abiomed, Inc. ($ABMD) reported Q3 2021 earnings of $1.17, beating the consensus estimate of $1.15.
The company's Q3 revenue reached a record $232 million, a 5% year-over-year increase, with a 31% operating margin.
Abiomed guided Q4 2021 revenue to $225-235 million, with a beat on Q3 earnings and revenue expectations.

Analysts· Nov 2

BTIG Research upgraded Abiomed ($ABMD) from neutral to buy with a $450 price target.
LEERINK reiterated an Outperform rating on Abiomed ($ABMD) with a price target of $450.
BTIG Research upgraded Abiomed ($ABMD) from neutral to buy with a $450 price target.

Announcements· Dec 22

Johnson & Johnson has completed its acquisition of Abiomed for $380 per share in cash, plus one non-tradeable contingent value right (CVR) of up to $35.
The acquisition was completed with 57% of Abiomed shares tendered, and Abiomed will operate as a standalone business within Johnson & Johnson's MedTech segment.
Abiomed has received FDA approval for its Impella ECP Pivotal heart pump, and the first patients have been enrolled in the pivotal clinical trial.

Technical Analysis· Oct 29

$ABMD has formed a bottom with a 28% decline, with some traders seeing this as a buying opportunity.
The stock is showing a golden cross on the 15-minute chart, indicating a potential upward trend.
A Fibonacci retracement level of 0.38 has been identified as a possible upside target for the stock.

Generated by AI

Community

Of the messages about ABMD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	2.5%
Newcomers	—	—	100%	97.5%

Regulars· Dec 22

Abiomed's quarterly revenue growth rate YoY is 7.20%, ranking 2445 out of 5752 companies in the database.
Johnson & Johnson has completed its acquisition of Abiomed, with the company filing necessary forms with the SEC, including a Form 14D9/A and Form SC TO-T/A.
Abiomed's Impella ECP Pivotal has been approved by the FDA, with the first patients enrolled in the pivotal clinical trial.

Newcomers· Dec 22

The acquisition of Abiomed by Johnson & Johnson has been completed, with Abiomed shareholders receiving $380 in cash plus a non-tradeable CVR worth up to $35.
Newcomers are adding to their positions in Abiomed, citing the potential for a top 3 position in their portfolio and a good risk-to-reward ratio.
Abiomed is expected to operate as a standalone business within Johnson & Johnson's MedTech segment, with a positive trend in trading volumes and a potential price target for next week.

Generated by AI

Abiomed

Social

Dec 27

Bullish· Nov 1

Bearish· Nov 1

Earnings· Jan 28

Analysts· Nov 2

Announcements· Dec 22

Technical Analysis· Oct 29

Regulars· Dec 22

Newcomers· Dec 22

J&J's MedTech Performance Slows in Q2: Will Sales Improve in H2?

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

J&J medtech miss overshadows earnings beat

Also Discussed

Abiomed, Inc.

Company Information

Location

Social

Dec 27

Bullish· Nov 1

Bearish· Nov 1

Earnings· Jan 28

Analysts· Nov 2

Announcements· Dec 22

Technical Analysis· Oct 29

Regulars· Dec 22

Newcomers· Dec 22

J&J's MedTech Performance Slows in Q2: Will Sales Improve in H2?

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

J&J medtech miss overshadows earnings beat

Also Discussed